

Applicant: Robert E. Reiter, et al.
U.S. Serial No.: 09/854,811
Filed: May 14, 2001
Page 2

Please amend the subject application as follows:

In the claims:

In compliance with the voluntary practice guidelines for making amendments, Applicants present all pending claims with status indicators.

Please cancel claims 54-57 and 75-76 without prejudice to pursue the subject matter of these claims in an application to be filed in the future.

Please amend claim 53 and 73 and add new claims 77-97 as follows:

1 to 52. (Canceled)

53. (Currently Amended) A method for inducing ~~an~~ a cellular immune response in a human subject directed to a PSCA protein of Fig. 1B (SEQ ID NO:2) in a subject having a cancer expressing a Prostate Stem Cell Antigen (PSCA) protein, comprising administering to the subject a PSCA protein fragment comprising a portion of a PSCA protein of Fig. 1B (SEQ ID NO:2) ~~or Fig 2 (SEQ ID NO:4).~~

54 to 57. (Canceled)

58. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 2 through 50 as described in SEQ ID NO:2.

59. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 85 through 123 as described in SEQ ID NO:2.

Applicant: Robert E. Reiter, et al.
U.S. Serial No.: 09/854,811
Filed: May 14, 2001
Page 3

60. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 46 through 109 as described in SEQ ID NO:2.
61. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 18 through 98 as described in SEQ ID NO:2.
62. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 22 through 99 as described in SEQ ID NO:2.
63. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 21 through 50 as described in SEQ ID NO:2.
64. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 46 through 85 as described in SEQ ID NO:2.
65. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 50 through 64 as described in SEQ ID NO:2.
66. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 67 through 81 as described in SEQ ID NO:2.

Applicant: Robert E. Reiter, et al.

U.S. Serial No.: 09/854,811

Filed: May 14, 2001

Page 4

67. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 21 through 99 as described in SEQ ID NO:2.
68. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 71 through 82 as described in SEQ ID NO:2.
69. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 85 through 99 as described in SEQ ID NO:2.
70. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 18 through 50 as described in SEQ ID NO:2.
71. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 46 through 98 as described in SEQ ID NO:2.
72. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 85 through 98 as described in SEQ ID NO:2.
73. (Currently amended) The method of claim 53, wherein the cancer cells expressing the PSCA protein is prostate cancer, prostate cancer metastasized to bone, ovarian cancer, tonsil cancer, ~~bladder cancer~~, stomach cancer, kidney cancer, testicular cancer, small intestinal cancer, colon cancer, or pancreatic cancer.

Applicant: Robert E. Reiter, et al.
U.S. Serial No.: 09/854,811
Filed: May 14, 2001
Page 5

74. (Previously presented) The method of claim 53, wherein the protein fragment consists of amino acid residues 1 through 123 as described in SEQ ID NO:2.

75 to 76. (Canceled)

77. (New) The method of claim 53 wherein the administering step further comprises administering dendritic cells.

78. (New) A method for inducing an immune response in a mammalian subject, comprising administering to the subject a PSCA protein fragment comprising a portion of a PSCA protein of Fig. 1B (SEQ ID NO:2).

79. (New) The method of claim 78 wherein the immune response is a humoral response, whereby an antibody is produced.

80. (New) The method of claim 78, wherein the subject is a human.

81. (New) The method of claim 78, wherein the subject is a sheep, rat, dog, cat, pig, horse, or mouse.

82. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 2 through 50 as described in SEQ ID NO:2.

83. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 85 through 123 as described in SEQ ID NO:2.

84. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 46 through 109 as described in SEQ ID NO:2.

Applicant: Robert E. Reiter, et al.
U.S. Serial No.: 09/854,811
Filed: May 14, 2001
Page 6

85. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 18 through 98 as described in SEQ ID NO:2.
86. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 22 through 99 as described in SEQ ID NO:2.
87. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 21 through 50 as described in SEQ ID NO:2.
88. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 46 through 85 as described in SEQ ID NO:2.
89. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 50 through 64 as described in SEQ ID NO:2.
90. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 67 through 81 as described in SEQ ID NO:2.
91. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 21 through 99 as described in SEQ ID NO:2.
92. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 71 through 82 as described in SEQ ID NO:2.
93. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 85 through 99 as described in SEQ ID NO:2.

Applicant: Robert E. Reiter, et al.

U.S. Serial No.: 09/854,811

Filed: May 14, 2001

Page 7

94. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 18 through 50 as described in SEQ ID NO:2.
 95. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 46 through 98 as described in SEQ ID NO:2.
 96. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 85 through 98 as described in SEQ ID NO:2.
 97. (New) The method of claim 78, wherein the protein fragment consists of amino acid residues 1 through 123 as described in SEQ ID NO: 2.
-